J&J Pauses Dosing of COVID-19 Vaccine Due to Blood Clotting

Share this

J&J Pauses Dosing of COVID-19 Vaccine Due to Blood Clotting


  • J&J temporarily pause the use of the COVID-19 vaccine in the US- following recommended of the CDC and FDA. The review data involves six reported cases of a rare and severe type of blood clot in the US after receiving the J&J vaccine
  • The pause is due to the unusual clotting in 6 women aged 18-48 with symptoms occurring in 6-13 days after vaccination- in combination with reduced platelet counts. Additionally- J&J delay the rollout of the vaccine in the EU and pause vaccinations in all COVID-19 vaccine clinical trials
  • The similar blood clot problem seen in AstraZeneca’s COVID 19 vaccine- as reported by several EU countries which prompted curbs to its use

Source 1 - Source 2  Ref: J&J | Image: Reuters

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions